




DX-2504



532A-X53-C02



532A-X54-B03

Figure 1



DX-2504
188
98
62
49
38
28
17
14
6
3
2H/2L
2H/1L
2H
532A-X53-B03
188
98
62
49
38
28
17
14
6
3
532A-X54-C02
188
98
62
49
38
28
17
14
6
3

Figure 2



% Monomer at 25 mg/mL in Citrate-Phosphate Buffer at 37 °C - Timecourse
100.00%
98.00%
96.00%
94.00%
92.00%
90.00%
% Monomer
T0 Days
T15 Days
T30 Days
Time point
DX-2504
532A-X53-C02
532A-X54-B03

Figure 3





FcRn isolates monomer product across pH gradient -
T=15days, room temperature
% Monomer
100.00%
80.00%
60.00%
40.00%
20.00%
0.00%
pH: 2.0
pH: 3.0
pH: 4.0
pH: 6.0
pH: 8.3
pH
DX-2504
532A-X54-C02
532A-X53-B03

Figure 4

532A-X54-C02



532A-X53-B03



DX-2504




Figure 5



IgG Stability against GuHCl Measured by Intrinsic Florescence
Intensity Ratio F360/F330
1.4
1.2
1.0
0.8
0.6
0M
1M
2M
3M
4M
5M
6M
7M
8M
GuHCl (M)
DX2504
X54-B03
X53-C02

Figure 6

pH 6.0




Figure 7

pH 7.5





Figure 8

	FR1-L	CDR1-L	FR2-L	CDR2-L
DX-2504:	QSALTQPASVSGSPGQSITISC	TGTGSDVGSYNLVS	WYQQHPGKAPKLMIY	GDSQRPS
532A-X53-C02	QSALTQPASVSGSPGQSITISC	TGTGSDVGSYNLVS	WYQQHPGKAPKLMIY	GDSQRPS
532A-X54-B03	QSALTQPASVSGSPGQSITISC	TGTGSDVGSYNLVS	WYQQHPGKAPKLMIY	GDSQRPS

	FR3-L	CDR3-L	FR4-L
DX-2504:	GVSNRFSGSKSGNTASLTISGLQAEDEADYYC	CSYAGSGIYV	FGTGTKVTVL
532A-X53-C02	GVSNRFSGSKSGNTASLTISGLQAEDEADYYC	SSYAGSGIYV	FGTGTKVTVL
532A-X54-B03	GVSNRFSGSKSGNTASLTISGLQAEDEADYYC	ASYAGSGIYV	FGTGTKVTVL

Figure 9


Fab 310
H-CDR3 Length Distribution
Frequency
60
50
40
30
20
10
0
1
5
9
13
17
21
25
29
Length (# residues)




Anti-FcRn H-CDR3 length distribution
Frequency
20
18
16
14
12
10
8
6
4
2
0
1
4
7
10
13
16
19
22
25
28
More
Length (# residues)

Figure 10


pH Dependent Binding of phagemid to Bio-shFcRn
shFcRn pH 6
SA-pH 6
shFcRn pH 7.5
SA-pH 7.5
Abs
2.5000
2.0000
1.5000
1.0000
0.5000
0.0000
Fab 1
Fab 2
Fab 3
Fab 4
Fab 5
Fab 6



B2M Binding
Bio-B2M
SA
Abs
1.0000
0.5000
0.0000
Fab 1
Fab 2
Fab 3
Fab 4
Fab 5
Fab 6

Figure 11



Vehicle
DX2500
M80-F11
M161-B04
M171-A01
hIgG in serum (mg/ml)
10
1
0.1
i.v. 20 mg/kg Ab
0
50
100
150
200
250
300
350
Time (hr)
i.v. 500 mg/kg hIgG

Figure 12



100
90
80
70
60
50
40
30
20
10
0
Anti-FcRn mAb (ng/mL)
0
2
4
6
8
10
12
14
Study Day
DX-2504
DX-2507

Figure 13



200
180
160
140
120
100
80
60
40
20
0
Total IgE (% Day 0)
0
5
10
15
20
25
30
35
40
Study Day
DX-2930
DX-2507
Study Drug Administration

Figure 14